Shandong Wohua Pharmaceutical Co., Ltd. (SHE:002107)
China · Delayed Price · Currency is CNY 5.95
-0.09 (-1.49%)
Jul 30, 2026, 3:04 PM CST
SHE:002107 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 779.46 | 812.08 | 758.76 | 905.1 | 1,013 | 941.8 |
Other Revenue | 5.49 | 4.87 | 5.04 | 4.4 | 1.89 | 0.88 |
| 784.94 | 816.95 | 763.79 | 909.51 | 1,015 | 942.67 | |
Revenue Growth | -1.14% | 6.96% | -16.02% | -10.38% | 7.65% | -6.30% |
Cost of Revenue | 179.74 | 203.07 | 210.83 | 234.75 | 255.27 | 214.94 |
Gross Profit | 605.21 | 613.89 | 552.97 | 674.76 | 759.55 | 727.74 |
Selling, General & Admin | 429.28 | 473.38 | 463.38 | 569.12 | 588.31 | 473.06 |
Research & Development | 32.72 | 36.39 | 40.65 | 45.35 | 50.11 | 47.48 |
Other Operating Expenses | 15.65 | 14.35 | 12.9 | 15.19 | 17.6 | 16.14 |
Operating Expenses | 476.88 | 524.46 | 515.9 | 627.71 | 657.74 | 535.77 |
Operating Income | 128.33 | 89.43 | 37.06 | 47.05 | 101.81 | 191.97 |
Interest Expense | -0.04 | -0.06 | -0.02 | -0.04 | -0.03 | -4.7 |
Interest & Investment Income | 3.15 | 5.81 | 4.93 | 5.23 | 4.67 | 6.79 |
Other Non Operating Income (Expenses) | -0.95 | 3.41 | -2.94 | -0.82 | -1.65 | -1.16 |
EBT Excluding Unusual Items | 130.49 | 98.58 | 39.04 | 51.43 | 104.81 | 192.91 |
Impairment of Goodwill | - | - | - | - | - | -13.54 |
Gain (Loss) on Sale of Assets | 0 | - | - | - | 2.15 | - |
Asset Writedown | -0.13 | -0.17 | -0.03 | -0.06 | -0.44 | -0.02 |
Legal Settlements | -1.28 | -1.29 | -0.13 | -0.14 | -0.26 | -0.53 |
Other Unusual Items | 7.37 | 5.26 | 3.77 | 3.41 | 4.54 | 11.13 |
Pretax Income | 136.45 | 102.38 | 42.65 | 54.64 | 110.79 | 189.96 |
Income Tax Expense | 17.81 | 13.59 | 8.89 | 8.01 | 20.91 | 28.63 |
Earnings From Continuing Operations | 118.65 | 88.79 | 33.76 | 46.63 | 89.89 | 161.32 |
Minority Interest in Earnings | -0.04 | 6.92 | 2.64 | 12.14 | 17.5 | 2.07 |
Net Income | 118.61 | 95.72 | 36.4 | 58.77 | 107.39 | 163.39 |
Net Income to Common | 118.61 | 95.72 | 36.4 | 58.77 | 107.39 | 163.39 |
Net Income Growth | 69.44% | 162.93% | -38.05% | -45.27% | -34.28% | -8.66% |
Shares Outstanding (Basic) | 565 | 563 | 607 | 588 | 565 | 584 |
Shares Outstanding (Diluted) | 565 | 563 | 607 | 588 | 565 | 584 |
Shares Change | -7.16% | -7.20% | 3.24% | 3.98% | -3.15% | 1.13% |
EPS (Basic) | 0.21 | 0.17 | 0.06 | 0.10 | 0.19 | 0.28 |
EPS (Diluted) | 0.21 | 0.17 | 0.06 | 0.10 | 0.19 | 0.28 |
EPS Growth | 82.50% | 183.33% | -40.00% | -47.37% | -32.14% | -9.68% |
Free Cash Flow | 133.09 | 127.66 | 87.69 | 126.53 | 178.49 | 181.04 |
Free Cash Flow Per Share | 0.23 | 0.23 | 0.14 | 0.21 | 0.32 | 0.31 |
Dividend Per Share | 0.263 | 0.266 | - | 0.250 | - | 0.260 |
Dividend Growth | 119.17% | - | - | - | - | 0% |
Gross Margin | 77.10% | 75.14% | 72.40% | 74.19% | 74.85% | 77.20% |
Operating Margin | 16.35% | 10.95% | 4.85% | 5.17% | 10.03% | 20.36% |
Profit Margin | 15.11% | 11.72% | 4.77% | 6.46% | 10.58% | 17.33% |
Free Cash Flow Margin | 16.96% | 15.63% | 11.48% | 13.91% | 17.59% | 19.20% |
EBITDA | 158.67 | 120 | 69 | 79.57 | 136.79 | 225.02 |
EBITDA Margin | 20.21% | 14.69% | 9.03% | 8.75% | 13.48% | 23.87% |
D&A For EBITDA | 30.34 | 30.57 | 31.93 | 32.52 | 34.99 | 33.05 |
EBIT | 128.33 | 89.43 | 37.06 | 47.05 | 101.81 | 191.97 |
EBIT Margin | 16.35% | 10.95% | 4.85% | 5.17% | 10.03% | 20.36% |
Effective Tax Rate | 13.05% | 13.27% | 20.84% | 14.66% | 18.87% | 15.07% |
Revenue as Reported | 784.94 | 816.95 | 763.79 | 909.51 | 1,015 | 942.67 |